Maxim Group Downgrades Mast Therapeutics (MSTX) to Hold Following Vepoloxamer Phase 3 Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Maxim Group Downgrades Mast Therapeutics (MSTX) to Hold Following Vepoloxamer Phase 3 Miss

Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell Disease

September 20, 2016 5:00 PM EDT

SAN DIEGO, Sept. 20, 2016 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today reported top-line results from EPIC, a Phase 3 clinical study of its investigational new drug vepoloxamer (also known as MST-188) for the treatment of individuals with sickle cell disease experiencing vaso-occlusive crisis (VOC).  The study did not meet its primary efficacy endpoint of demonstrating a statistically significant reduction in the mean... More